血清miRNAs在甲状腺乳头状癌诊断和预后评估中的研究进展  

Research progress of serum miRNAs in the diagnosis and prognosis of papillary thyroid carcinoma

作　　者：马震(综述)[1] 王薇(审校)[1] Ma Zhen;Wang Wei(Second Department of General Surgery,Affiliated Hospital of traditional Chinese Medicine,Xinjiang Medical University,Xinjiang Province,Urumqi 830011,China)

机构地区：[1]新疆医科大学附属中医医院普外二科,乌鲁木齐830011

出　　处：《疑难病杂志》2023年第6期661-664,共4页Chinese Journal of Difficult and Complicated Cases

基　　金：新疆维吾尔自治区自然科学基金项目(2020D01C146)。

摘　　要：miRNAs是具有21~23个核苷酸的非编码RNA,在进化过程中高度保守,被认为是基因表达、细胞凋亡、癌症以及细胞生长和分化的调节因子。血清miRNA水平可作为甲状腺癌诊断及预后的分子标志物。鉴于大多数筛查甲状腺癌的常用方法不能在疾病的早期阶段检测,而检测血液中的miRNAs被认为是甲状腺癌早期诊断的关键方法。文章就血清miRNAs作为甲状腺乳头状癌诊断和预后的生物标志物研究进行阐述。MiRNAs are non coding RNAs with 21⁃23 nucleotides,which are highly conserved in the process of evo⁃lution.They are considered to be regulators of gene expression,apoptosis,cancer,and cell growth and differentiation.Serum miRNA level can be used as a molecular marker for the diagnosis and prognosis of thyroid cancer.Since most common meth⁃ods for screening thyroid cancer cannot be detected in the early stage of the disease,the detection of miRNAs in blood is con⁃sidered to be the key method for the early diagnosis of thyroid cancer.This article reviews the research on serum miRNA as a biomarker for the diagnosis and prognosis of papillary thyroid cancer.

关 键 词：甲状腺乳头状癌 血清miRNAs 生物标志物 

分 类 号：R736.1[医药卫生—肿瘤]